Sort By Date
  • Summer 2022
    From April 21 – 23, 2022, I was honored to attend the 3rd VIPOC (Vitiligo International Patient Organizations Conference) in Amsterdam, Netherlands.
  • Spring Newsletter 2022
    As we step into a new year, I feel somewhat hopeful, as well as thankful, that we seem to be inching our way back toward the life we once knew....
  • Winter Newsletter 2021
    As we step into a new year, I feel somewhat hopeful, as well as thankful, that we seem to be inching our way back toward the life we once knew....
  • VSI: Fall Edition Newsletter 2021
    Fall Newsletter 2021
    I started this message to announce the good news that on September 21, 2021, the JAK inhibitor, ruxolitinib cream (Opzelura™), was approved by the FDA for the treatment of atopic...
  • Summer Newsletter 2021
    With the emails, phone calls, meetings, conference calls, regulatory registrations, licenses, renewals, funding requirements, donor relations, bookkeeping, IRS filings, ongoing education, research, deadlines, newsletters ..... and other associated day-to-day responsibilities...
  • Spring Newsletter 2021
    I’d like to begin with a round of applause for VSI members! On 2/12/21, VSI sent out an email announcement about the (then) upcoming FDA “Patient-Focused Drug Development Meeting for...
  • Winter Newsletter 2020
    Each year as I compose my year-end message, I reflect on the year’s developments, events, news, etc., in a vitiligo “state-of-the-year” sort of way. While the work of research, advocacy,...
  • Fall Newsletter 2020
    I receive a number of daily medical updates from a variety of sources, and one recently caught my attention. The Dermatology Practice Update “Story of the Week,” titled “Availability of...
  • Summer Newsletter 2020
    It seems like a lifetime has passed since the message I wrote for the Spring newsletter when COVID-19 was beginning its epic spread. I don’t think many of us could...

VSI Newsletter Archives